Clinical Outcomes of Anticoagulant Therapy in COVID-19 Patients with Pre-Existing Cardiovascular Diseases: A Systematic Review

References

• Klok FA, Kruip MJ, Van der Meer NJ, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–150. doi:10.1016/j.thromres.2020.04.041
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020;181(2):271–280.
   PubMed Web of Science ®Google Scholar
• Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID‐19: a systematic review and meta‐analysis. Res Practice Thrombosis Haemostasis. 2020;14(7):12439–12452.
   Google Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973.
   PubMed Web of Science ®Google Scholar
• Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268–277.
   PubMed Web of Science ®Google Scholar
• Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. J Thrombosis Haemostasis. 2020;18(7):1743–1746.
   PubMed Web of Science ®Google Scholar
• Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost. 2020;46(7):772–776.
   PubMedGoogle Scholar
• Ghosh R, Roy D, Mandal A, et al. Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr. 2022;15(3):1039–1045.
   Web of Science ®Google Scholar
• Hu H. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2021;42(1):206–213.
   PubMedGoogle Scholar
• Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020;41(22):2130–2137.
   PubMed Web of Science ®Google Scholar
• Sánchez-Recalde Á, Solano-López J, Miguelena-Hycka J, Martín-Pinacho JJ, Sanmartín M, Zamorano JL. COVID-19 and cardiogenic shock. Different cardiovascular presentations with high mortality. Rev Esp Cardiol. 2020;73(8):669–672.
   Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818.
   PubMed Web of Science ®Google Scholar
• Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831–840.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• Fried JA, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020;141(23):1930–1936.
   PubMed Web of Science ®Google Scholar
• Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122(6):743–752.
   PubMed Web of Science ®Google Scholar
• Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Em Microbes Infections. 2020;9(1):727–732.
   PubMed Web of Science ®Google Scholar
• Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thrombosis Haemostasis. 2020;18(5):1094–1099.
   PubMed Web of Science ®Google Scholar
• Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5(20):3951–3959.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Harrison SL, Buckley BJ, et al. Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. Cardiovasc Diabetol. 2021;20(1):1.
   PubMed Web of Science ®Google Scholar
• Fröhlich GM, Jeschke E, Eichler U, et al. Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. Clin Res Cardiol. 2021;110(2):1041–1050.
   PubMedGoogle Scholar
• O’Gallagher K, Shek A, Bean DM, et al. Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19. BMC Cardiovasc Disord. 2021;21(1):1–3.
   PubMed Web of Science ®Google Scholar
• Spiegelenberg JP, van Gelder MM, Maas ML, et al. Prior use of therapeutic anticoagulation does not protect against COVID‐19 related clinical outcomes in hospitalized patients: a propensity score‐matched cohort study. Br J Clin Pharmacol. 2021;87(12):4839–4847.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chen P, Li H, Chen C, Wang F, Wang DW. Mortality and pre‐hospitalization use of low‐dose aspirin in COVID‐19 patients with coronary artery disease. J Cell Mol Med. 2021;25(2):1263–1273.
   PubMed Web of Science ®Google Scholar
• Rieder M, Gauchel N, Kaier K, et al. Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities. Clin Res Cardiol. 2022;111(3):322–332.
   PubMed Web of Science ®Google Scholar
• Arachchillage DJ, Rajakaruna I, Odho Z, et al. Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK—a multicentre observational study. Br J Haematol. 2022;196(1):79–94.
   PubMed Web of Science ®Google Scholar
• Palmieri L, Vanacore N, Donfrancesco C, et al. Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy. J Gerontol. 2020;75(9):1796–1800.
   Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng j Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41(22):2083–2088.
   PubMed Web of Science ®Google Scholar
• Razi M, Gu J, He X, Kong J, Ahmed MJ. Venous thromboembolism in patients with COVID-19. A prevalent and a preventable complication of the pandemic. J Interventional Med. 2021;4(2):62–65.
   PubMedGoogle Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836.
   PubMed Web of Science ®Google Scholar
• Dofferhoff AS, Piscaer I, Schurgers LJ, et al. Reduced vitamin K status as a potentially modifiable risk factor of severe coronavirus disease 2019. Clin Infectious Dis. 2021;73(11):4039–4046.
   Web of Science ®Google Scholar
• Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–124.
   PubMed Web of Science ®Google Scholar
• Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–40.
   PubMed Web of Science ®Google Scholar
• Ueyama H, Kuno T, Ando T, et al. Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists after transcatheter aortic valve implantation. Am J Cardiol. 2020;125(7):1102–1107.
   PubMed Web of Science ®Google Scholar
• Michael F, Natt N, Shurrab M. Direct oral anticoagulants vs vitamin K antagonists in left ventricular thrombi: a systematic review and meta-analysis. CJC Open. 2021;3(9):1169–1181.
   PubMedGoogle Scholar
• Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thrombosis Haemostasis. 2020;18(6):1320–1323.
   PubMed Web of Science ®Google Scholar
• Chow JH, Khanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg. 2021;132(4):930–941.
   PubMed Web of Science ®Google Scholar